Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01595581
Other study ID # HS-11-00649
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 2012
Est. completion date May 2015

Study information

Verified date February 2022
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being done to test whether taking testosterone can prevent loss of muscle mass and strength due to anterior cruciate ligament (ACL) reconstructive surgery. Testosterone is the principal male sex hormone and an anabolic (muscle promoting) steroid. It is essential for the development of male reproductive tissues and promotes increased muscle, bone mass, and the growth of body hair. The investigators hope to learn whether testosterone given before and after ACL reconstructive surgery will increase muscle mass and strength and potentially improve recovery time following surgery.


Description:

Overall Objective: The overall objective of this study is to determine if 8 weeks of testosterone first administered 2 weeks prior to surgery, can improve the outcome of anterior cruciate ligament (ACL) reconstruction. Overall Hypothesis: Standard-of-care rehabilitation with the addition of testosterone administration will augment muscle mass, strength, and physical function following ACL reconstructive surgery compared to standard rehabilitation alone. Significance: Muscle mass and strength are greatly reduced following ACL surgery. The investigators hypothesize that administration of testosterone will minimize these reductions or potentially increase muscle mass and strength. In doing so, testosterone may hasten a patient's return to physical activity. If testosterone improves recovery after ACL surgery, the same treatment may be used for other injuries that involve trauma and muscle atrophy. Furthermore, this study will examine the effect of trauma with or without testosterone on myogenic regulators in muscle tissue taken during ACL surgery-providing possible mechanistic insights for the clinical outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - A complete ACL tear as visualized on MRI - The ACL injury can be either "isolated" or combined with one or several of the following injuries visualized on MRI and/or arthroscopy: - a meniscus tear that is either left untreated or treated with a partial resection - a small, stable meniscus tear treated with fixation, but with the fixation not interfering with the rehabilitation protocol - cartilage changes verified on MRI with an arthroscopically determined intact surface. - A radiographic examination with normal joint status or combined with either one of the following findings: - a small-avulsed fragment located laterally, usually described as a Segond fracture, JSN grade 1 or osteophytes grade 1 as determined by the OARSI atlas15 Exclusion Criteria: - Previous major knee injury or knee surgery - Associated posterior cruciate ligament (PCL) or medical collateral ligament (MCL) injury grade III - Concomitant severe injury to contra-lateral knee - Injury to the lateral/posterolateral ligament complex with significantly increased laxity - Unstable longitudinal meniscus tear that requires repair and where the following postoperative treatment (we.e. bracing and limited range of motion) interferes with the rehabilitation protocol - Bi-compartmental extensive meniscus resections - Cartilage injury representing a full thickness loss down to bone - Total rupture of MCL/LCL as visualized on MRI. - History of deep vein thrombosis (DVT) or a disorder of the coagulative system - Claustrophobia - Prior or current use of anabolic steroids - General systemic disease affecting physical function - Chromosomal disorders - Medications that interfere with testosterone production or function, including but not limited to 5a-reductase inhibitors - Any other condition or treatment interfering with the completion of the trial

Study Design


Intervention

Drug:
Testosterone
8 weeks of testosterone administration beginning 2 weeks before ACL surgery
Placebo
8 weeks of saline administration beginning 2 weeks before ACL surgery

Locations

Country Name City State
United States University of Southern California Los Angeles California

Sponsors (3)

Lead Sponsor Collaborator
University of Southern California Boston University, University of Oregon

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Lean Mass Relative changes in lean mass from 2 weeks prior to surgery to 6 weeks, 12 weeks, and 24 weeks following surgery between the two groups. 6, 12, and 24 weeks post operative
Secondary KOOS Scores Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) from 2 weeks prior to surgery to 6, 12, and 24 weeks post surgery.
KOOS is scored from 0 to 100 with 0 representing extreme knee problems and 100 representing normal knee function.
6 weeks, 12 weeks, 24 weeks post surgery
Secondary Strength Changes in muscle strength from the start of rehabilitation to 6, 12, and 24 weeks following surgery between the two groups in the injured limb. 6, 12, and 24 weeks post surgery
See also
  Status Clinical Trial Phase
Completed NCT04657926 - A Trial of APPA in the Treatment of Knee Osteoarthritis Phase 2
Completed NCT02536833 - A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Phase 2
Completed NCT03014037 - Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration N/A
Recruiting NCT05937542 - A Qualitative Investigation of CLEAT Participants
Completed NCT03644615 - A Mindfulness Program (MBSR) in the Management of Symptomatic Hip and Knee Osteoarthritis N/A
Recruiting NCT06061367 - Muscles Strength and Gait Parameteres After TKA
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT03850665 - Comparison of Functional Outcome in Patients After Hip Arthroplasty Depending on Surgical Approach N/A
Completed NCT02826902 - Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial N/A
Completed NCT04402502 - Dynamic 4DCT to Examine Wrist Carpal Mechanics N/A
Completed NCT02923700 - Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial Phase 4
Completed NCT04564053 - Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants Phase 1
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Not yet recruiting NCT05036174 - Diphenhydramine Ointment for Knee Osteoarthritis N/A
Recruiting NCT02912429 - Onlay vs. Inlay Patellofemoral Arthroplasty N/A
Recruiting NCT02666443 - Low Dose Dexamethasone in Supraclavicular Blocks N/A
Active, not recruiting NCT02723929 - Effects of tDCS and tUS on Pain Perception in OA of the Knee
Terminated NCT02820766 - Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting N/A
Withdrawn NCT02921594 - Kinematic Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties N/A